idea-005 · desirability deck
Every slide states a condition that would have to be true, then reports where it stands using the candidate file's own claim and its own confidence tag. A deck never upgrades a tag, invents a number, or recommends anything, and there is no ask slide.
The chair: the parents of a child waiting for a sleep study, the pediatric sleep physician who reads it, and the ENT who would operate on the strength of it.
How to read this: every slide is a condition, not a conclusion. A bracketed claim reference points into knowledge-base/candidates/idea-005.md — the number is the claim's position in its ## Claims list, the tag is copied from it and never adjusted here. A [no claim] marker means nothing in the file speaks to the condition at all. See docs/deck-spec.md.
What changed since the 2026-08-24 build — this deck's central statement is now wrong and has been replaced. That build said this candidate "has no verified claims at all". It now has seven claim 26verified through claim 32verified, and they are the most consequential evidence in this file. One of them answers this deck's load-bearing question directly, and the answer is adverse. Rebuilt from the file, not patched.
Would have to be true: Children referred for suspected OSA (obstructive sleep apnoea) would have to be waiting long enough for an in-lab bed that a home study is worth the trade — and there would have to be enough of them.
Where it stands: The wait is now evidenced, though not in the US: in a Québec quality-improvement study of 82 consecutive pediatric adenotonsillectomy patients, mean referral-to-consultation delay was 9.0±7.0 months and total referral-to-surgery delay was 15.2±8.6 months, substantially exceeding the region's own surgical access targets claim 32verified. That is a real, verified measure of how slow this pathway is — in a single-payer Canadian system, which is not the US market this candidate launches into, and the claim carries jurisdiction: US while describing non-US data. The US wait-list premise stays unbacked claim 15unconfirmed, as do referral volume and obtainable share claim 5unconfirmed, claim 7unconfirmed. Prevalence is verified and wide: the 2012 AAP technical report reviewing 3,166 titles found pediatric OSAS prevalence ranging from 0% to 5.7% across the literature claim 29verified.
What would settle it: US pediatric sleep centre wait-time data, human-attached — AASM accredited-centre surveys or a children's hospital's own queue; a commercial or Medicaid claims extract for pediatric PSG (polysomnography) volume, since Medicare will not show it.
If it's false: There is no problem to move out of the lab, and the candidate's stated obtainable segment is measuring a queue that may not exist at the size assumed.
Would have to be true: A parent would have to fit a cannula, a thermistor, two effort belts and an oximeter probe on their own child at bedtime — and the child would have to sleep in it, first try.
Where it stands: Both halves remain unbacked for this device claim 16unconfirmed, claim 17unconfirmed — and the best available evidence says this is not where the product fails. In an Australian study of 47 children aged 5-16 undergoing home Type-2 polysomnography, acceptable recordings were obtained for every home study attempted claim 31verified. Read that carefully before taking comfort from it: a Type-2 montage includes EEG, so it is a heavier setup than the one this candidate proposes, and it succeeded anyway. Home application by families is, on this evidence, a solved problem. The candidate's difficulty lies elsewhere.
What would settle it: First-night technical failure rates from the pediatric HSAT (home sleep apnoea test) literature and from the registered trials the file points at claim 4unconfirmed — those trials measure exactly this and their protocols are public.
If it's false: Repeat studies erase the cost advantage over the in-lab test, and the parent's experience of failure is worse than the wait would have been.
Would have to be true: A pediatric sleep physician would have to read an unattended study as sufficient, and an ENT would have to operate on the strength of it.
Where it stands: This is now answered at the level of professional-society guidance, and it is answered no. The AASM's 2017 Position Paper states that use of a home sleep apnea test is not recommended for the diagnosis of obstructive sleep apnea in children — and the stated reason is an inability to identify literature on HSAT devices that monitor CO2 or detect arousals, measurements the task force viewed as critical in pediatric populations claim 28verified. That objection is not incidental to this candidate; arousal detection requires EEG, and an EEG-free montage is precisely what this product proposes. The individual clinician questions remain unbacked claim 14unconfirmed, claim 18unconfirmed, but they now sit downstream of a published position rather than in open space.
What would settle it: Interviews with pediatric sleep physicians and pediatric otolaryngologists on how much the 2017 position actually binds their practice, and what evidence would move it — the position paper is nine years old and the concordance literature has grown since claim 30verified. AAO-HNS practice guidance on home testing in children, read by a human.
If it's false: The result becomes a triage tool that still ends in a lab study for anyone being considered for surgery — a smaller product than the one described, and one whose reimbursement argument no longer works.
Would have to be true: The burden of a home study — equipment, a disrupted night, a possible repeat — would have to stay under the burden of the wait plus the lab night it replaces, and the risk of being wrong would have to be acceptable.
Where it stands: The wait side of the trade is now quantified, if non-US claim 32verified. The accuracy side has verified numbers for the first time, and they are better than the last build could report: a 6.6% false-positive and 3% false-negative rate for OSA diagnosis in the Australian home cohort claim 31verified — again, on a Type-2 montage that includes EEG. The candidate's own dominant risk remains false negatives on an EEG-free montage claim 11unconfirmed, and the verified prevalence range is wide enough that the pre-test probability varies a great deal by population claim 29verified. What a family would actually be charged is still unknown claim 8unconfirmed.
What would settle it: A payer policy read for what a family would actually be charged; and the false-negative rate for the EEG-free montage specifically, which claim 31verified does not supply.
If it's false: The product is asking families to accept a diagnostic with a known blind spot in exchange for convenience — a trade a paediatrician will frame for them, not a marketer.
Would have to be true: There would have to be a concurrent-PSG validation in children, in this age range, showing agreement good enough that a specialist changes practice.
Where it stands: Partly, and the qualification matters more than the result. A 2026 systematic review of pediatric HSAT-versus-PSG concordance found that only 3 of 9 included studies used simultaneous HSAT and PSG testing — and in one of the largest of those, mean AHI was 2.5±3 by HSAT versus 2.7±2.9 by PSG, p>0.05 claim 30verified. So concurrent evidence exists, is favourable where it exists, and is thin: three studies. That is simultaneously the best argument this candidate has and a precise description of the gap its own multi-site study claim 12unconfirmed would fill. Against it stands the AASM position claim 28verified and the AAP's finding that most diagnostic screening tests in this condition had low sensitivity and specificity claim 29verified.
What would settle it: Read the three simultaneous studies inside claim 30verified for their montages and thresholds — the cheapest act on this deck, and the one that determines whether the candidate's study is a replication or a first. Then the registered trials' protocols claim 4unconfirmed.
If it's false: There is nothing to persuade with, and the belief question stays where it is today — with specialists who require a lab study claim 14unconfirmed.
Would have to be true: Ten conversations with pediatric sleep physicians and ENTs, plus the public trial records, would have to tell you whether this is wanted before the multi-million dollar study is commissioned.
Where it stands: Still no primary research, and the file records an honest failure to substitute for it: parent preference was written up as "unanswerable directly", and a US-specific PSG no-show, cancellation or dropout rate was searched for and not found claim 33unconfirmed. The nearest revealed-behaviour evidence is the referral-delay study claim 32verified, which quantifies the burden of the in-lab pathway but says nothing about uptake of a home alternative. (Note: claim 33unconfirmed points at "claim 38unverified" for that twin; the file has 33 claims and the study it describes is claim 32verified.)
What would settle it: The clinician interviews, framed around the device that already exists rather than the one proposed — and framed around claim 28verified, which is the document those clinicians will cite back.
If it's false: The idea is a regulatory strategy in search of a clinical demand, and the demand was assumed from a queue nobody measured claim 15unconfirmed.
Every condition above with nothing verified behind it.
The file's premise was refuted and that remains the most important structural fact here: a cleared home airflow/effort recorder already states verbatim that "both pediatric and adult patients may be tested" claim 3refuted, from a roster of 38 MNR clearances. The user's access to home testing was never blocked by clearance. What the seven new verified claims add is a candidate answer to "then what is stopping them": a professional society that does not recommend it, for a reason that names the channel this device omits claim 28verified.
If only one thing from this chair could be checked: whether pediatric sleep physicians and ENTs will act on an unattended study in an otherwise-healthy child claim 14unconfirmed, claim 18unconfirmed.
It stays load-bearing, and its character has changed from open question to contested one. If clearance were the barrier, the candidate's plan would be the answer; but a device permitting pediatric home testing is already cleared claim 3refuted and the practice has not moved. The last build listed coverage claim 8unconfirmed and clinical acceptance claim 14unconfirmed as the two candidate explanations. There is now verified evidence for the second: the AASM does not recommend HSAT for pediatric OSA diagnosis, citing the absence of arousal and CO2 monitoring claim 28verified.
That does not settle it — a 2017 position is not a permanent one, the concordance literature has grown since claim 30verified, and no claim in this file establishes how strongly that position binds individual practice. But it changes what the multi-site study claim 12unconfirmed would have to accomplish: not merely demonstrate agreement, but demonstrate it well enough to move a stated society position whose objection is aimed at this device's architecture.
Naming it is not a recommendation, a gate, or a kill.
_shared/plain-language.md